Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) just unveiled an announcement.
Percheron Therapeutics has announced a change in director James Garner’s holdings following his participation in the company’s recent entitlement offer. The director acquired 21,400,000 fully paid ordinary shares and 10,700,000 unquoted options for a total consideration of $107,000, increasing his stake to 74,900,000 shares and a larger portfolio of unquoted options with varying exercise prices and maturities.
The transaction reflects direct participation in the capital raising initiative, indicating confidence from senior leadership in the company’s strategy and outlook. This increased alignment between the director’s financial interests and those of shareholders may be viewed positively by the market, as it strengthens governance incentives and supports the broader equity raising effort announced in March 2026.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the biopharmaceutical sector, focusing on the development and commercialization of therapeutic products. The company is listed on the ASX and raises capital through equity offerings, including entitlement offers to existing shareholders, to fund its operations and growth initiatives.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
See more data about PER stock on TipRanks’ Stock Analysis page.